#1225 on the rich list of 14,452 insiders
Terrance P. Coyne
EVP & CFO at Royalty Pharma. Based in New York, New York.
$132M
in disclosed stock, −$1.8M (−1.38%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
- Rank
- 1225th of 14,452
- Companies held
- 1
- Largest holding
- RPRX, 100.0% of total
- Latest SEC filing
- Nov 16, 2026
What the $132M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Royalty Pharma RPRX Class E Ordinary Shares | Indirectly (see filing footnote) | 1,788,777 | $67.72 | $121M | 91.9% | Form 4, Aug 7, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | TPC RP, LLC | 100,000 | $67.72 | $6.8M | 5.1% | Form 4, Nov 6, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Spouse's IRA | 24,170 | $67.72 | $1.6M | 1.2% | Form 4, Nov 16, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through IRA | 23,270 | $67.72 | $1.6M | 1.2% | Form 4, Nov 16, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | TPC RP EPA1 LLC | 7,122 | $67.72 | $482K | 0.4% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Directly | 1,500 | $67.72 | $102K | 0.1% | Form 4, Nov 16, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Spouse | 1,450 | $67.72 | $98K | 0.1% | Form 4, Nov 16, 2026 |
Share counts are the amounts Terrance P. Coyne reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Sold | RPRX | 14,751 | $68.30 | $1.0M | View |
| Nov 17, 2026 | Sold | RPRX | 9,835 | $68.30 | $672K | View |
| Nov 16, 2026 | Sold | RPRX | 135,249 | $68.87 | $9.3M | View |
| Nov 16, 2026 | Sold | RPRX | 90,165 | $68.87 | $6.2M | View |
| Nov 16, 2026 | Sold | RPRX | 7,122 | $68.87 | $490K | View |
| Aug 13, 2026 | Sold | RPRX | 9,230 | $58.59 | $541K | View |
| Aug 13, 2026 | Sold | RPRX | 1,772 | $59.14 | $105K | View |
| May 26, 2026 | Sold | RPRX | 64,399 | $53.98 | $3.5M | View |
| Apr 28, 2026 | Sold | RPRX | 1,875 | $49.78 | $93K | View |
| Apr 28, 2026 | Sold | RPRX | 32,916 | $49.78 | $1.6M | View |
| Apr 1, 2026 | Sold | RPRX | 32,916 | $48.33 | $1.6M | View |
| Apr 1, 2026 | Sold | RPRX | 1,875 | $48.33 | $91K | View |
| Mar 23, 2026 | Sold | RPRX | 32,916 | $45.53 | $1.5M | View |
| Mar 23, 2026 | Sold | RPRX | 1,875 | $45.53 | $85K | View |
| Mar 2, 2026 | Sold | RPRX | 1,292 | $46.67 | $60K | View |
| Mar 2, 2026 | Sold | RPRX | 10,429 | $47.01 | $490K | View |
| Mar 2, 2026 | Sold | RPRX | 22,487 | $46.67 | $1.0M | View |
| Mar 2, 2026 | Sold | RPRX | 583 | $47.01 | $27K | View |
| Feb 23, 2026 | Sold | RPRX | 32,916 | $45.32 | $1.5M | View |
| Feb 23, 2026 | Sold | RPRX | 1,875 | $45.32 | $85K | View |
| Feb 4, 2026 | Sold | RPRX | 1,087 | $43.29 | $47K | View |
| Feb 4, 2026 | Sold | RPRX | 19,076 | $43.29 | $826K | View |
| Feb 3, 2026 | Sold | RPRX | 6,195 | $42.84 | $265K | View |
| Feb 3, 2026 | Sold | RPRX | 108,759 | $42.84 | $4.7M | View |
| Feb 2, 2026 | Sold | RPRX | 5,843 | $42.08 | $246K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 1222 | Thomas P. Salice Director, Mettler-Toledo International | $132M |
| 1223 | Marjorie Gershwind 10% owner, MSC Industrial Direct Co.. Melville, NY | $132M |
| 1224 | Gregory L. Christopher Chairman of the Board & CEO, Mueller Industries. Germantown, TN | $132M |
| 1225 | Terrance P. Coyne EVP & CFO, Royalty Pharma. New York, NY | $132M |
| 1226 | Michael R. Haske Chief Operating Officer, Paylocity Holding. Schaumburg, IL | $132M |
| 1227 | Yun Yao 10% owner, Indaptus Therapeutics. New York, NY | $131M |
| 1228 | Ben Hakim President, Pershing Square. New York, NY | $131M |
Other Royalty Pharma insiders
All RPRX insiders- Pablo G. Legorreta$335MCEO, Chairman of the Board. #516 overall
- George W. Lloyd$184MEVP, Investments & CLO. #939 overall
- James F. Reddoch$57.3MEVP & Chief Scientific Officer. #2308 overall
- Rory B. Riggs$28.5MDirector. #2664 overall
- Christopher Hite$13.6MEVP & Chairman, Partnering. #6962 overall
- Gregory Norden$13.3MDirector. #6522 overall
Questions
How much stock does Terrance P. Coyne own?
Terrance P. Coyne holds $131,802,691 in listed stock based on SEC filings and current prices, mostly Royalty Pharma (RPRX). That ranks 1225th on the Stock Rich List.
Is this Terrance P. Coyne's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Terrance P. Coyne last buy or sell stock?
The most recent open-market trade on file is a sale of 14,751 RPRX shares on Nov 17, 2026 at $68.30.